Annexon Biosciences CEO Doug Love considers Guillain-Barré syndrome — also known as GBS — to be the “most unique disease” he’s worked on in 25 years in biotech because of its sudden onset. A rare ...
MUMBAI, Jan 27 (Reuters) - One person is believed to have died in India's Maharashtra state in an outbreak of Guillain-Barre syndrome (GBS) - a neurological disease that causes numbness, weakness and ...
Currently, there is no known way to prevent GBS. However, getting vaccinated against certain infections and practising good ...
MONTREAL — An investigational targeted immunotherapy for Guillain-Barré syndrome (GBS) more than doubled improvement in disability after 8 weeks compared with placebo and showed sustained benefit at ...
Paralytic diseases are spreading in Gaza as an Israeli blockade continues to prevent medicine and food from coming in. Since June, 85 suspected cases of Guillain-Barre syndrome (GBS) have been ...
Researchers in Norway studied rates of fatalities and long-term neurodevelopmental disorders among 866 infants diagnosed with GBS infection. Children with GBS meningitis died at higher rates than ...
Everyday Health on MSN
What’s the difference between chronic inflammatory demyelinating polyneuropathy and Guillain-Barré syndrome?
Learn the key differences between CIDP and GBS, including causes, onset, and treatments, to ensure you get the correct diagnosis.
The last time I wrote about Annexon (ANNX) it was with respect to a Seeking Alpha article entitled "Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place". In this article ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results